Molecular Senescence, Neuroendocrine Metaflammation, And Skeletal Muscle Insulin Resistance In Type-4 Diabetes: From Mitochondrial Dysfunction To Precision Therapeutics
As our global population ages, a significant yet often overlooked contributor to diabetes in older adults is emerging: insulin resistance driven by the natural decline of muscle mass, a condition known as sarcopenia. This research delves into a distinct form of diabetes, termed type-4 diabetes, which is intimately linked to the aging process.
At its core, this type of diabetes involves several key mechanisms. Firstly, as muscle cells age, they become resistant to insulin, the hormone that helps sugar enter cells for energy. This age-driven insulin resistance leads to a “bioenergetic collapse” in the mitochondria, which are the powerhouses of our cells. Essentially, these cellular energy factories stop working efficiently, causing energy problems.
Furthermore, the body experiences a prolonged, low-grade inflammation, referred to as “neuroendocrine metaflammation,” involving both the nervous and hormonal systems. Aging, dysfunctional muscle cells, called senescent cells, release inflammatory signals that create a self-reinforcing cycle of inflammation. The paper also points to issues with how insulin signals within cells, how glucose is transported, and how the body regulates energy. Oxidative stress, a state where there are too many harmful molecules called reactive oxygen species, also damages the genetic material within mitochondria.
Imbalances in certain hormones, such as myostatin, irisin, and FGF21, further disrupt glucose control. Other contributing factors include insulin resistance in the brain, inflammation in brain cells, an imbalance of gut bacteria, and changes in gene expression without altering the DNA sequence itself.
Looking forward, the paper suggests that a more precise diagnosis can be achieved by using specific biological markers and by analyzing multiple biological data sets, such as genes and proteins. For treatment, the research proposes innovative strategies including drugs that remove aging cells, methods to boost a molecule called NAD+, activators of a protein called SIRT1, and therapies to clear damaged mitochondria. Additionally, treatments targeting myostatin and exosome-based therapies are being explored to shift metabolic care towards addressing the root causes of aging-related metabolic decline.
Source: link to paper